Drug Trial Radar · NCT07063745
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
590
Planned (sponsor's estimate)
Start
Jan 2, 2026
Primary completion
Aug 12, 2031
Study completion Aug 12, 2031
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
Conditions
- Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Interventions
BMS-986504Drug
Specified dose on specified days
PembrolizumabDrug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
CisplatinDrug
Specified dose on specified days
CarboplatinDrug
Specified dose on specified days
PemetrexedDrug
Specified dose on specified days
PaclitaxelDrug
Specified dose on specified days
Nab-paclitaxelDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) by RECIST v1.1Time frame: Up to 2 years
- PFS by RECIST v1.1 per BICRTime frame: Up to 5 years
- Overall Survival (OS)Time frame: Up to 5 years
Locations
321 sites in 34 countries. Site status is shown where the registry gives one.
Local Institution - 0119
Anchorage, Alaska · Completed
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona · Recruiting
University of Arizona Cancer Center
Tucson, Arizona · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
Local Institution - 0497
Los Alamitos, California · Not yet recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Local Institution - 0444
Los Angeles, California · Withdrawn
Local Institution - 0606
Newark, Delaware · Withdrawn
Helios Clinical Research - Fort Lauderdale
Fort Lauderdale, Florida · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Local Institution - 0430
St. Petersburg, Florida · Withdrawn
Local Institution - 0523
Tampa, Florida · Not yet recruiting
St. Luke's Cancer Institute: Boise
Boise, Idaho · Recruiting
Cancer Care Specialists of Illinois - Cancer Care Center of O'Fallon
Decatur, Illinois · Recruiting
Baptist Health Lexington
Lexington, Kentucky · Recruiting
University of Kentucky Chandler Medical Center
Lexington, Kentucky · Recruiting
Local Institution - 0127
Scarborough, Maine · Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Local Institution - 0418
Ann Arbor, Michigan · Not yet recruiting
Local Institution - 0405
Detroit, Michigan · Not yet recruiting
Local Institution - 0420
Traverse City, Michigan · Not yet recruiting
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota · Recruiting
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Local Institution - 0467
Lebanon, New Hampshire · Not yet recruiting
Local Institution - 0600
Manchester, New Hampshire · Not yet recruiting
WMCHealth Advanced Physician Services
Hawthorne, New York · Recruiting
Local Institution - 0128
Rochester, New York · Not yet recruiting
Ellis Hospital
Schenectady, New York · Recruiting
Local Institution - 0514
Winston-Salem, North Carolina · Not yet recruiting
Local Institution - 0163
Cleveland, Ohio · Withdrawn
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Providence Portland Medical Center
Portland, Oregon · Recruiting
Kaiser Permanente Interstate Medical Office Central
Portland, Oregon · Recruiting
Local Institution - 0559
Hershey, Pennsylvania · Withdrawn
Local Institution - 0608
Greenville, South Carolina · Not yet recruiting
Local Institution - 0515
Knoxville, Tennessee · Withdrawn
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
Dallas, Texas · Recruiting
Local Institution - 0374
El Paso, Texas · Completed
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Local Institution - 0377
The Woodlands, Texas · Withdrawn
Showing 40 of 321 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.